Abstract
The aim: To determine the optimal qualitative and quantitative composition of auxiliary substances for tablets containing dry extract of Acorus calamus leaves and the solid dispersion of quercetin, their relatively therapeutic dose and antiexudative activity. Materials and methods: This study determined a relatively therapeutic dose of dry extract of Acorus calamus leaves, investigated the impact of various auxiliary substances on the properties of tablets formulated with active ingredients - dry extract of Acorus calamus leaves and solid dispersion of quercetin, and assessed antiexudative activity these tablets. The comprehensive analysis entailed the utilization of standardized pharmacopoeial methods to evaluate the quality of the tablet samples. These methods encompassed a range of assessments designed to ensure that the tablets met the requisite pharmacological standards, focusing on key characteristics such as dissolution rate and stability. Determination of the relatively therapeutic dose and antiexudative activity made using standard pharmacological methods in laboratory rats. Results: In-depth exploration during the study led to identifying Ac-Di-Sol and Lubripharm SSF as the most suitable auxiliary substances for the tablet composition. Detailed analysis revealed that Ac-Di-Sol, when utilized at a 10 % concentration, markedly improved the tablets' disintegration rate without adversely affecting their structural integrity. Concurrently, Lubripharm SSF was observed to significantly enhance the tablets' mechanical stability by reducing their friability. Conclusions: As a result of the study, the relatively therapeutic dose of dry extract of Acorus calamus leaves, and the solid dispersion of quercetin, optimal auxiliary substances for the tablet formulation - Ac-Di-Sol and Lubripharm SSF - were established. The conducted research enabled the development of a tablet composition that aligns with the requisite pharmacotechnological specifications and conditions of the modern pharmaceutical industry and demonstrates high antiexudative activity relative to monocomponent substances and famous drugs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
